Inogen (INGN)
(Delayed Data from NSDQ)
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Zacks News
Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered
by Zacks Equity Research
Inogen (INGN) slashes revenue and net income guidance for 2019.
Inogen (INGN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Inogen's (INGN) first-quarter 2019 results are expected to get a boost from product launches.
Why the Earnings Surprise Streak Could Continue for Inogen (INGN)
by Zacks Equity Research
Inogen (INGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Launches One G5 Portable Oxygen Concentrator
by Zacks Equity Research
Inogen's (INGN) product launch is in line with the company's strategy of providing innovative and long-term oxygen therapy to patients in need of respiratory aid.
Inogen (INGN) Down 12.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bull of the Day: DexCom (DXCM)
by Kevin Cook
Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator
Inogen's Prospects in Europe Solid Amid Trade-Related Tension
by Zacks Equity Research
Inogen's (INGN) business-to-business unit sees strength in Europe.
Inogen (INGN) Q4 Earnings Beat Estimates, Rental Revenues Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.
Inogen Gains From Commercial Launch of Wireless Connect
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio lends it a competitive edge in the respiratory care devices market.
Why Is Inogen (INGN) Down 7.9% Since Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.
Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Inogen (INGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (INGN) Outperforming Other Medical Stocks This Year?
Inogen (INGN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 40.38% and 4.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Top Stock Picks for the Week of November 5th
by Panel Of Zacks Experts
Two Companies Outperforming Their Industries.
Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.
Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips
by Zacks Equity Research
Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.
Inogen (INGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Inogen (INGN) closed the most recent trading day at $192.30, moving +0.6% from the previous trading session.
NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
NuVasive (NUVA) registers balanced growth across its couple of business wings.
Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.
Inogen (INGN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y
by Zacks Equity Research
Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.
Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises
by Zacks Equity Research
Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises
Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.